THE FACTS
BRIEF POINTS.
Less Harmful Methods of Consumption:
Many novel cannabinoids are consumed in forms like tinctures, capsules, or edibles, which reduce the health risks associated with smoking or vaping. These consumption methods are generally considered safer for lung health.
Growing Body of Research:
While Delta-8, Delta-9, and THCA are newer in the market, initial studies and widespread anecdotal evidence suggest they are relatively safe when used responsibly. Most adverse reactions are mild, such as dry mouth or mild dizziness, especially in lower doses.
Widespread Consumer Use with Minimal Reports of Severe Side Effects:
Millions of consumers use these cannabinoids regularly, with relatively few reports of severe side effects. While regulation and purity standards are still being established, most products are considered safe by users when purchased from reputable sources with third-party lab testing.
Less Addictive Potential:
Current evidence suggests that Delta-8 THC has a lower risk of addiction compared to Delta-9 THC, making it a safer option for recreational and medicinal users who are concerned about dependency.
SCIENTIFIC STUDIES.
Delta-8-THC: Delta-9-THC’s nicer younger sibling?
Journal of Cannabis Research
Delta-8-THC may provide much of the experiential benefits of delta-9-THC with lesser adverse effects. Future systematic research is needed to confirm participant reports, although these studies are hindered by the legal statuses of both delta-8-THC and delta-9-THC. Cross-sector collaborations among academics, government officials, and representatives from the cannabis industry may accelerate the generation of knowledge regarding delta-8-THC and other cannabinoids. A strength of this study is that it is the first large survey of delta-8 users, limitations include self-report data from a self-selected convenience sample.
An efficient new cannabinoid antiemetic in pediatric oncology
Department of Pediatrics, Shaare Zedek Hospital, Jerusalem, Israel
Delta-8-tetrahydrocannabinol (delta-8-THC), a cannabinoid with lower psychotropic potency than the main Cannabis constituent, delta-9-tetrahydrocannabinol (delta-9-THC), was administered (18 mg/m2 in edible oil, p.o.) to eight children, aged 3-13 years with various hematologic cancers, treated with different antineoplastic drugs for up to 8 months. The total number of treatments with delta-8-THC so far is 480. The THC treatment started two hours before each antineoplastic treatment and was continued every. 6 hrs for 24 hours. Vomiting was completely prevented. The side effects observed were negligible.